Join Growin Stock Community!

Heartsciences inc.HSCSW.US Overview

US StockHealthcare
(No presentation for HSCSW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HSCSW AI Insights

HSCSW Overall Performance

HSCSW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HSCSW Recent Performance

0.09%

Heartsciences inc.

0.05%

Avg of Sector

-0.31%

S&P500

HSCSW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HSCSW Key Information

HSCSW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HSCSW Profile

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Price of HSCSW

HSCSW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HSCSW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-676.84%
Net Margin
-104237.91%
Revenue Growth (YoY)
-41.03%
Profit Growth (YoY)
16.78%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
219.38%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-676.84%
Net Margin
-104237.91%
Revenue Growth (YoY)
-41.03%
Profit Growth (YoY)
16.78%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
219.38%
  • When is HSCSW's latest earnings report released?

    The most recent financial report for Heartsciences inc. (HSCSW) covers the period of 2026Q2 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HSCSW's short-term business performance and financial health. For the latest updates on HSCSW's earnings releases, visit this page regularly.

  • What is the operating profit of HSCSW?

    According to the latest financial report, Heartsciences inc. (HSCSW) reported an Operating Profit of -2.07M with an Operating Margin of -85,713.23% this period, representing a decline of 4.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HSCSW's revenue growth?

    In the latest financial report, Heartsciences inc. (HSCSW) announced revenue of 2.42K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does HSCSW have?

    At the end of the period, Heartsciences inc. (HSCSW) held Total Cash and Cash Equivalents of 1.95M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HSCSW go with three margins increasing?

    In the latest report, Heartsciences inc. (HSCSW) did not achieve the “three margins increasing” benchmark, with a gross margin of 60%%, operating margin of -98,637.84%%, and net margin of -108.16%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HSCSW's profit trajectory and future growth potential.

  • Is HSCSW's EPS continuing to grow?

    According to the past four quarterly reports, Heartsciences inc. (HSCSW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HSCSW?

    Heartsciences inc. (HSCSW)'s Free Cash Flow (FCF) for the period is -2.35B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 107,112.23% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of HSCSW?

    The latest valuation data shows Heartsciences inc. (HSCSW) has a Price-To-Earnings (PE) ratio of -0.49 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.